Abbott taps Fleishman for hepatitis C treatment PR

ABBOTT PARK, IL: Pharmaceutical company Abbott Laboratories hired Fleishman-Hillard to handle PR for its hepatitis C portfolio following a competitive review.

ABBOTT PARK, IL: Pharmaceutical company Abbott Laboratories hired Fleishman-Hillard to handle PR for its hepatitis C portfolio following a competitive review.

Earlier this month, a study showed that an experimental drug mixture from Abbott wiped out the virus that causes hepatitis C in 99% of patients. Abbott is competing with other companies such as Bristol-Myers Squibb to develop hepatitis C drugs that will replace the standard injection that patients receive.

Hepatitis C affects an estimated 180 million people worldwide, and the market for new therapies could reach $20 billion by 2020.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in